These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7914739)

  • 21. Slow-acting anti-rheumatic drug therapy for rheumatoid arthritis.
    Clegg DO; Ward JR
    Nurse Pract; 1987 Mar; 12(3):44, 49-52. PubMed ID: 2882451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.
    Smith MD
    Curr Opin Rheumatol; 1989 Jun; 1(1):74-9. PubMed ID: 2577111
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of disease modifying anti-rheumatic drugs on radiographic progression in rheumatoid arthritis].
    Yukawa N; Mimori T
    Clin Calcium; 2009 Mar; 19(3):395-403. PubMed ID: 19252250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current concepts in the management of rheumatoid arthritis.
    Murphy NG
    Del Med J; 1992 Apr; 64(4):257-64. PubMed ID: 1352263
    [No Abstract]   [Full Text] [Related]  

  • 25. The role of anti-malarials in rheumatoid arthritis--the American experience.
    Khraishi MM; Singh G
    Lupus; 1996 Jun; 5 Suppl 1():S41-4. PubMed ID: 8803910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rheumatoid arthritis therapy: the slow-acting agents.
    Hardin JG
    Hosp Pract (Off Ed); 1989 Jun; 24(6):163-8, 170, 173-8. PubMed ID: 2566617
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials.
    Felson DT; Anderson JJ; Meenan RF
    Arthritis Rheum; 1992 Oct; 35(10):1117-25. PubMed ID: 1358078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Combination therapy of disease-modifying antirheumatic drugs(DMARDs) in rheumatoid arthritis].
    Kobayashi S; Kanai Y
    Nihon Rinsho; 2002 Dec; 60(12):2351-6. PubMed ID: 12510361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
    Aletaha D; Smolen JS
    Rheumatology (Oxford); 2002 Dec; 41(12):1367-74. PubMed ID: 12468815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy of rheumatoid arthritis--rationale and overview.
    Jaffe IA
    J Rheumatol Suppl; 1990 Nov; 25():24-7. PubMed ID: 1980314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
    Simon LS
    Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis.
    Nagashima M; Matsuoka T; Saitoh K; Koyama T; Kikuchi O; Yoshino S
    Clin Exp Rheumatol; 2006; 24(3):260-7. PubMed ID: 16870092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis.
    Galindo-Rodriguez G; Avina-Zubieta JA; Fitzgerald A; LeClerq SA; Russell AS; Suarez-Almazor ME
    J Rheumatol; 1997 Apr; 24(4):633-8. PubMed ID: 9101493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
    Kremer JM
    Ann Intern Med; 2001 Apr; 134(8):695-706. PubMed ID: 11304108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands.
    van Jaarsveld CH; Jacobs JW; van der Veen MJ; Blaauw AA; Kruize AA; Hofman DM; Brus HL; van Albada-Kuipers GA; Heurkens AH; ter Borg EJ; Haanen HC; van Booma-Frankfort C; Schenk Y; Bijlsma JW
    Ann Rheum Dis; 2000 Jun; 59(6):468-77. PubMed ID: 10834865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical studies with salazopyrine--consequences and perspectives].
    Zeidler H
    Z Rheumatol; 1987; 46(2):59-66. PubMed ID: 2885985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
    van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
    Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical therapy: where are we now?
    Resman-Targoff BH
    Am J Health Syst Pharm; 2006 Sep; 63(18 Suppl 4):S11-8. PubMed ID: 16960243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Weekly low-dose methotrexate in rheumatoid arthritis. Review of the literature].
    Manganelli P; Troise Rioda W
    Minerva Med; 1993 Oct; 84(10):541-52. PubMed ID: 8247309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
    Koyama Y; Shiraishi H; Ohta T; Uchino A
    Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.